Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adriamycin + vindesine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of adriamycin (the brand name for doxorubicin) and vindesine. Doxorubicin is an anthracycline antibiotic that acts as a cytotoxic agent by intercalating DNA, inhibiting topoisomerase II, and generating free radicals leading to DNA damage and cell death[3][6]. Vindesine is a vinca alkaloid that inhibits microtubule formation in mitotic spindle fibers, thereby arresting cell division at metaphase. The combination of these two agents targets cancer cells through complementary mechanisms—doxorubicin disrupts DNA processes while vindesine impairs mitosis—making the regimen effective against rapidly dividing tumor cells. This combination has been used in the treatment of various cancers including lymphomas and sarcomas.
- Other names
- doxorubicin + vindesinedoxorubicin hydrochloride + vindesine
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on adriamycin + vindesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adriamycin + vindesine.